DK0603305T3 - Anvendelse af et thymosin til behandling af hepatitis C - Google Patents

Anvendelse af et thymosin til behandling af hepatitis C

Info

Publication number: DK0603305T3
Authority: DK; Denmark
Prior art keywords: thymosin; treat hepatitis; immune system; potentiating; hepatitis
Prior art date: 1991-09-13

Application number

DK92919977.6T

Other languages

English (en)

Inventor

Milton Mutchnick

Kenneth E Sherman

Paul Chretian

Original Assignee

Alpha 1 Biomedicals Inc

Univ Wayne State

Us Army

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-09-13

Filing date

1992-09-08

Publication date

1997-09-01

1992-09-08 Application filed by Alpha 1 Biomedicals Inc, Univ Wayne State, Us Army filed Critical Alpha 1 Biomedicals Inc

1997-09-01 Application granted granted Critical

1997-09-01 Publication of DK0603305T3 publication Critical patent/DK0603305T3/da

Links

LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title abstract 5
108010046075 Thymosin Proteins 0.000 title abstract 4
102000007501 Thymosin Human genes 0.000 title abstract 4
208000005176 Hepatitis C Diseases 0.000 title 1
108010078233 Thymalfasin Proteins 0.000 abstract 1
102400000800 Thymosin alpha-1 Human genes 0.000 abstract 1
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 1
229960004231 thymalfasin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Beans For Foods Or Fodder (AREA)

DK92919977.6T 1991-09-13 1992-09-08 Anvendelse af et thymosin til behandling af hepatitis C DK0603305T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US75954491A	1991-09-13	1991-09-13

Publications (1)

Publication Number	Publication Date
DK0603305T3 true DK0603305T3 (da)	1997-09-01

Family

ID=25056052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92919977.6T DK0603305T3 (da)	1991-09-13	1992-09-08	Anvendelse af et thymosin til behandling af hepatitis C

Country Status (23)

Country	Link
US (3)	US6001799A (da)
EP (1)	EP0603305B1 (da)
JP (1)	JP3228512B2 (da)
KR (1)	KR100254082B1 (da)
AT (1)	ATE152914T1 (da)
AU (1)	AU667327B2 (da)
CA (1)	CA2119006C (da)
CZ (1)	CZ286827B6 (da)
DE (1)	DE69219782T2 (da)
DK (1)	DK0603305T3 (da)
ES (1)	ES2103966T3 (da)
FI (1)	FI107879B (da)
GR (1)	GR3024025T3 (da)
HK (1)	HK1021687A1 (da)
HU (1)	HU221006B1 (da)
MX (1)	MX9205240A (da)
NO (1)	NO941310D0 (da)
RO (1)	RO111991B1 (da)
RU (1)	RU2104010C1 (da)
SG (1)	SG64897A1 (da)
TW (1)	TW224053B (da)
WO (1)	WO1993005806A1 (da)
ZA (1)	ZA926964B (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW224053B (da) *	1991-09-13	1994-05-21	Paul B Chretien
WO1995011688A1 (en) *	1992-02-06	1995-05-04	Sciclone Pharmaceuticals	Method for treating hepatitis b carriers with minimal disease
AU751199B2 (en) *	1992-07-13	2002-08-08	Government Of The United States Of America As Represented By The Secretary Of The Army	Composition and method of treating hepatitis B
EP0627930A4 (en) *	1992-07-13	1997-08-20	Kenneth E Sherman	COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
CN1072961C (zh) *	1993-03-05	2001-10-17	施塞克龙药品公司	治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en)	1993-06-02	2001-03-13	Sciclone Pharmaceuticals, Inc.	Combination therapy method for treating chronic hepatitis B
US5468729A (en) *	1993-10-26	1995-11-21	Alpha 1 Biomedicals	Method for treatment of autoimmune hepatitis
DK0731710T3 (da) *	1993-11-05	2003-06-16	Sciclone Pharmaceuticals Inc	Fremgangsmåde og præparat til behandling af patienter med inkompenseret leversygdom
JP3837769B2 (ja) *	1995-06-12	2006-10-25	大塚製薬株式会社	抗ウイルス剤
AU722987B2 (en) *	1996-02-28	2000-08-17	Unihart Corporation	Pharmaceutical compositions comprising natural human alpha-interferon
PY0111577A (es)	2000-05-23	2017-01-02	Idenix Cayman Ltd	Métodos y composiciones para el tratamiento del virus de la hepatitis c
AP2006003708A0 (en)	2000-05-26	2006-08-31	Idenix Cayman Ltd	Methods and compositions for treating flavivirusesand pestiviruses
US7208167B2 (en) *	2000-08-07	2007-04-24	Sciclone Pharmaceuticals, Inc.	Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002011749A1 (en) *	2000-08-07	2002-02-14	Sciclone Pharmaceuticals, Inc.	Treatment of hepatitis c with thymosin, interferon and ribavirin
WO2002044717A1 (en) *	2000-12-01	2002-06-06	Cornell Research Foundation	Animal model for flaviviridae infection
RU2211703C2 (ru) *	2001-06-08	2003-09-10	ООО НТЦ "Юпитер-2"	Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
AU2002330154A1 (en) *	2001-09-28	2003-04-07	Centre National De La Recherche Scientifique	Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US20050013801A1 (en) *	2001-10-05	2005-01-20	Hsu Henry H.	Methods of treating liver fibrosis and hepatitis c virus infection
IL161603A0 (en)	2001-10-26	2004-09-27	Rhode Island Hospital	Thymosin augmentation of genetic immunization
UA80957C2 (en) *	2001-11-01	2007-11-26	Sciclone Pharmaceuticals Inc	Method of administering a thymosin alpha 1 peptide
WO2003068162A2 (en) *	2002-02-14	2003-08-21	Pharmasset Ltd.	Modified fluorinated nucleoside analogues
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN1678326A (zh)	2002-06-28	2005-10-05	埃迪尼克斯(开曼)有限公司	用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
PT1523489E (pt)	2002-06-28	2014-06-24	Centre Nat Rech Scient	Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
CN101172993A (zh)	2002-06-28	2008-05-07	埃迪尼克斯(开曼)有限公司	用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
RU2005118421A (ru)	2002-11-15	2006-01-20	Айденикс (Кайман) Лимитед (Ky)	2'-разветвленные нуклеозиды и мутация flaviviridae
PL377287A1 (pl)	2002-12-12	2006-01-23	Idenix (Cayman) Limited	Sposób wytwarzania 2'-rozgałęzionych nukleozydów
GB0301879D0 (en) *	2003-01-27	2003-02-26	Regent Res Llp	HCV combination therapy
JP4149296B2 (ja) *	2003-03-26	2008-09-10	株式会社ルネサステクノロジ	半導体記憶装置
BRPI0408892A (pt) *	2003-03-28	2006-04-11	Sciclone Pharmaceuticals Inc	uso de timosina alfa 1 para tratar as infecções por arpergillus
PT1613340E (pt) *	2003-03-28	2010-08-19	Sciclone Pharmaceuticals Inc	Tratamento de infecções por aspergillus com timosina alfa 1
US20100311656A1 (en) *	2003-04-23	2010-12-09	Sciclone Pharmaceuticals, Inc.	Treatment or prevention of respiratory viral infections with alpha thymosin peptides
BRPI0419345B8 (pt)	2003-05-30	2021-05-25	Gilead Pharmasset Llc	uso do (2r)-2-desoxi-2-flúor-2-c-metil nucleosídeo e de uma composição farmacêutica que o compreende
DK1658302T3 (da)	2003-07-25	2010-11-22	Idenix Pharmaceuticals Inc	Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
WO2005021007A1 (fr) *	2003-08-28	2005-03-10	Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir'	Prevention et traitement de l'hepatite virale b
US7754718B2 (en)	2004-05-05	2010-07-13	Yale University	Antiviral helioxanthin analogs
CN101023094B (zh)	2004-07-21	2011-05-18	法莫赛特股份有限公司	烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
MX2007003085A (es)	2004-09-14	2007-08-02	Pharmasset Inc	Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
JP4516863B2 (ja) *	2005-03-11	2010-08-04	株式会社ケンウッド	音声合成装置、音声合成方法及びプログラム
JP5254033B2 (ja)	2005-12-23	2013-08-07	イデニクプハルマセウティカルス，インコーポレイテッド	分岐型ヌクレオシドを調製するための合成中間体の製造方法
EP1832295A1 (en) *	2006-03-10	2007-09-12	Tecnogen S.P.A.	Use of PTX3 for the treatment of viral diseases
DK2012816T3 (da) *	2006-05-02	2012-09-03	Sigma Tau Ind Farmaceuti	Anvendelse af Thymosin 1, alene eller i kombination med PTX3 eller Ganciclovir, til behandling af Cytomegalovirus infektion.
ES2288118B1 (es) *	2006-05-10	2008-11-01	Bcn Peptides, S.A.	Procedimiento para sintetizar timosinas.
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
TW200946541A (en) *	2008-03-27	2009-11-16	Idenix Pharmaceuticals Inc	Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
EP2349315A4 (en) *	2008-10-08	2012-07-04	Univ Miami	LYMPHOCYTE REGULATION AND APPLICATION
CL2009002206A1 (es)	2008-12-23	2011-08-26	Gilead Pharmasset Llc	Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
TW201026715A (en)	2008-12-23	2010-07-16	Pharmasset Inc	Nucleoside phosphoramidates
JP6104504B2 (ja)	2008-12-23	2017-03-29	ギリアドファーマセットエルエルシー	ヌクレオシド類似体
EP2427213B1 (en)	2009-05-08	2015-04-01	Sciclone Pharmaceuticals, Inc.	Alpha thymosin peptides as vaccine enhancers
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
CL2011000716A1 (es)	2010-03-31	2012-04-20	Gilead Pharmasset Llc	Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
PL3290428T3 (pl)	2010-03-31	2022-02-07	Gilead Pharmasset Llc	Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2012075140A1 (en)	2010-11-30	2012-06-07	Pharmasset, Inc.	Compounds
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
US8809354B2 (en)	2011-12-31	2014-08-19	Sheikh Riazuddin	3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) *	2012-11-09	2015-10-21	长春海悦药业有限公司	一种含有胸腺法新的药物组合物及其制剂
JP2016529293A (ja)	2013-08-27	2016-09-23	ギリアドファーマセットエルエルシー	２つの抗ウイルス化合物の組合せ製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1216056B (it) *	1988-03-11	1990-02-22	Sclavo Spa	Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) *	1991-03-29	1993-12-28	The George Washington University	Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (da) *	1991-09-13	1994-05-21	Paul B Chretien

1992
- 1992-03-16 TW TW081101971A patent/TW224053B/zh active
- 1992-09-08 WO PCT/US1992/007556 patent/WO1993005806A1/en not_active Ceased
- 1992-09-08 JP JP50608393A patent/JP3228512B2/ja not_active Expired - Fee Related
- 1992-09-08 HU HU9400758A patent/HU221006B1/hu not_active IP Right Cessation
- 1992-09-08 RU RU94022480A patent/RU2104010C1/ru active
- 1992-09-08 CA CA002119006A patent/CA2119006C/en not_active Expired - Lifetime
- 1992-09-08 ES ES92919977T patent/ES2103966T3/es not_active Expired - Lifetime
- 1992-09-08 CZ CZ1994551A patent/CZ286827B6/cs not_active IP Right Cessation
- 1992-09-08 KR KR1019940700603A patent/KR100254082B1/ko not_active Expired - Fee Related
- 1992-09-08 AT AT92919977T patent/ATE152914T1/de active
- 1992-09-08 EP EP92919977A patent/EP0603305B1/en not_active Expired - Lifetime
- 1992-09-08 HK HK98105712A patent/HK1021687A1/en not_active IP Right Cessation
- 1992-09-08 DK DK92919977.6T patent/DK0603305T3/da active
- 1992-09-08 RO RO94-00409A patent/RO111991B1/ro unknown
- 1992-09-08 AU AU26447/92A patent/AU667327B2/en not_active Ceased
- 1992-09-08 SG SG1996006295A patent/SG64897A1/en unknown
- 1992-09-08 DE DE69219782T patent/DE69219782T2/de not_active Expired - Lifetime
- 1992-09-11 ZA ZA926964A patent/ZA926964B/xx unknown
- 1992-09-14 MX MX9205240A patent/MX9205240A/es not_active IP Right Cessation
1993
- 1993-03-05 US US08/027,500 patent/US6001799A/en not_active Expired - Lifetime
- 1993-11-04 US US08/145,660 patent/US5849696A/en not_active Expired - Lifetime
1994
- 1994-03-10 FI FI941133A patent/FI107879B/fi not_active IP Right Cessation
- 1994-04-12 NO NO941310A patent/NO941310D0/no unknown
1997
- 1997-07-09 GR GR970401680T patent/GR3024025T3/el unknown
2007
- 2007-05-11 US US11/801,834 patent/US20070218033A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE69219782T2 (de)	1997-10-09
RO111991B1 (ro)	1997-04-30
CZ286827B6 (cs)	2000-07-12
HU221006B1 (hu)	2002-07-29
US20070218033A1 (en)	2007-09-20
JPH06510998A (ja)	1994-12-08
ATE152914T1 (de)	1997-05-15
NO941310L (no)	1994-04-12
CA2119006C (en)	2005-08-23
AU667327B2 (en)	1996-03-21
RU94022480A (ru)	1996-07-20
HU9400758D0 (en)	1994-06-28
TW224053B (da)	1994-05-21
GR3024025T3 (en)	1997-10-31
US6001799A (en)	1999-12-14
EP0603305B1 (en)	1997-05-14
FI941133L (fi)	1994-03-10
NO941310D0 (no)	1994-04-12
DE69219782D1 (de)	1997-06-19
FI941133A0 (fi)	1994-03-10
CA2119006A1 (en)	1993-04-01
HK1021687A1 (en)	2000-06-23
RU2104010C1 (ru)	1998-02-10
AU2644792A (en)	1993-04-27
FI107879B (fi)	2001-10-31
EP0603305A1 (en)	1994-06-29
MX9205240A (es)	1993-07-01
CZ55194A3 (en)	1994-10-19
JP3228512B2 (ja)	2001-11-12
KR100254082B1 (ko)	2000-09-01
SG64897A1 (en)	1999-05-25
ZA926964B (en)	1993-04-26
WO1993005806A1 (en)	1993-04-01
HUT75166A (en)	1997-04-28
US5849696A (en)	1998-12-15
ES2103966T3 (es)	1997-10-01

Publication	Publication Date	Title
NO941310L (no)	1994-04-12	Sammensetning og fremgangsmåte for behandling av hepatitt C
DK0537971T3 (da)	1997-07-07	Fremgangsmåde til administration af algoritme-uafhængige kryptografinøgler
DE69200447D1 (de)	1994-10-27	Erzeugung von russen.
FI932254A7 (fi)	1993-07-02	Menetelmä dipalmitoyylifosfaridyylikoliinidispersioiden antamiseksi
DE69103844D1 (de)	1994-10-13	Einstufiger Venenkatheter.
DE3667895D1 (de)	1990-02-01	Einrichtung zur erzeugung eines im wesentlichen homogenen plasmas.
DE3683586D1 (de)	1992-03-05	Behandlung des atemunwohlseinsyndroms bei erwachsenen.
DK234590A (da)	1990-09-28	Fremgangsmaade til behandling af retrovirusinfektioner
FI941705A0 (fi)	1994-04-13	Menetelmä viruspatogeenien läpipääsyn estämiseksi
DK81691D0 (da)	1991-05-02	Fremgangsmaade til forhindring eller reduktion af eosinofili
ATE155345T1 (de)	1997-08-15	Gegengift immunsera
DK0588873T3 (da)	1997-09-15	Behandling af levercancer
FI942552A0 (fi)	1994-05-31	Terapeuttisia menetelmiä käyttäen keesiumioneja
DK0687181T3 (da)	2001-10-01	Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling
DK0517787T3 (da)	1999-04-06	Fremgangsmåde til behandling af terapiresistent skizofreni med amperozide
ATE63463T1 (de)	1991-06-15	Behandlung chronischer entzuendungskrankheiten.
FI822018A7 (fi)	1982-12-11	Menetelmä puhtaan hepatiitti B pinta- antigeenin valmistamiseksi ihmisen plasmasta.
EP0096728A4 (en)	1984-01-16	PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST TYMPANITY.
FR2698652B1 (fr)	1995-03-17	Procédé et dispositifs de renforcement de planchers bois.
FI883864L (fi)	1989-02-22	Renoveringsmaskin.
NO893070L (no)	1990-01-29	Fremgangsmaate ved solubilisering.
DK27391D0 (da)	1991-02-15	Metode til oeget opbygget insulineffekt
ATE78181T1 (de)	1992-08-15	Mund-zu-mund-beatmungsmaske.
ES1007997Y (es)	1989-12-16	Aspirador perfeccionado de fondos de piscinas.